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The cellular binding and uptake was studied for cc,-inhibitor3, a monomeric 200 kDa proteinase inhibitor 
present in rat plasma. After intravenous injection in the rat the inhibitor disappeared from the circulation 
with a half-time of 2.5 min when complexed with chymotrypsin, whereas the half-time for uncomplexed 
Inhibitor was more than 60 min. 6 min after the injection of labelled complex, 83% was in the liver and 
2.5% in the spleen. In vitro experiments at 4°C with isolated hepatocytes and peritoneal macrophages 
showed binding to the previously described receptors which bind and internalize the tetrameric rat and hu- 
man al-macroglobulin-proteinase complexes. The binding affinities were similar for the two types of comple- 
xes and binding was followed by uptake and degradation of the labelled complex when the cells were 
warmed to 37°C. The binding of uncomplexed al-inhibitor3 was low and did not increase following treat- 
ment with methylamine in spite of cleavage of the internal thiol ester. cc,-Inhibitor3-methylamine was 
changed to the receptor binding form when treated with chymotrypsin which caused the cleavage of at least 
one peptide bond in the bait region. 
aI-Inhibitor3; cc?-Macroglobulin; Cellular receptor; Thiol ester 
1. INTRODUCTION 
The proteinase inhibitor designated cut-inhibitor3 
(atI3) was first isolated from rat plasma by 
Gauthier and Ohlsson [ 11. The molecular mass is 
about 200 kDa [2] and the concentration in normal 
rat plasma is about 30 PM. It is capable of interac- 
ting with elastase, chymotrypsin and trypsin [3-51. 
It was recently reported that 1 mol of SH groups 
is generated when 1 mol of ai13 interacts with 
1 mol of chymotrypsin or trypsin, that at least one 
peptide bond near the middle of the polypeptide 
chain is cleaved and that the formation of a stable 
complex is associated with a conformational 
change of the cut13 molecule. Moreover, treatment 
with methylamine also generated SH groups [6-91. 
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The results are analogous to those obtained when 
human cuz-macroglobulin interacts with a pro- 
teinase (review [lo]). These features strongly sug- 
gest that ~~113 is homologous to az-macroglobulin. 
In addition, recent partial sequence data from the 
N-terminus [lo] and the C-terminus of cut13 [ll] 
clearly demonstrate that (~113 is a member of the 
macroglobulin family of proteinase binding pro- 
teins. The present paper shows that ~ytI3 is also a 
homologue of cuz-macroglobulin in the sense that 
when complexed with chymotrypsin it binds to the 
same receptors in the two major target cells, 
hepatocytes and macrophages. 
2. MATER1AL.S AND METHODS 
Rat cu11~ was prepared from pooled EDTA plas- 
ma obtained from 200 g male Wistar rats essential- 
ly according to [8] employing polyethylene glycol 
precipitation, DEAE-Sephacel chromatography, 
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Zn-chelate chromatography and Sephacryl S-300 
gel chromatography. Approximately 170 mg ~yrI3 
was obtained from 76 ml plasma. The preparation 
contained 0.9 mol active ,!3-cysteinyl-y-glutamyl 
thiol ester as revealed by titration with 2,2’-di- 
thiobis-5nitrobenzoic acid of samples that had 
been incubated with an equimolar amount of tryp- 
sin, chymotrypsin, elastase or S. aureu.s protease. 
Non-denaturing PAGE and HPLC gel chromatog- 
raphy using columns of Superose 12 or TSK 
G-3000 SW demonstrated that freshly prepared 
cuiI3 migrated as a protein of approx. 200 kDa, 
consistent with earlier results [7-91. After pro- 
teinase complex formation, minor amounts (ap- 
prox. 5-10%) of dimers and tetramers were 
observed. 
Human [ 121 and rat [13] cuz-macroglobulin were 
prepared as described previously. The ligands were 
iodinated using 0.5 mol “‘1 per mol 200 kDa ~~113 
monomer or 180 kDa cuz-macroglobulin subunit as 
described in [14]. Labelled or unlabelled ~113 was 
complexed with a 1.5times molar excess of bovine 
chymotrypsin (Worthington, three times crystal- 
lized) for 3 min at 20°C followed by the addition 
of PMSF (phenylmethanesulfonyl fluoride) to a 
final concentration of 1 mM. cuz-Macroglobulin 
was complexed with trypsin as described [12]. The 
tracers were passed over a 0.5 x 3 cm Sephacryl S 
200 column before each experiment to remove low 
molecular mass decay products [ 
[ 151. Rat hepatocytes were prepared by 
perfusion of livers from 200-300 g ad lib fed male 
Wistar rats with collagenase followed by cen- 
trifugation in a preformed linear gradient of Per- 
co11 to remove Kupffer cells and damaged 
hepatocytes [ 161. Peritoneal macrophages were 
elicited by intraperitoneal injection of 3 ml 
thioglycolate (260 mg/ml). The rat was killed after 
4 days by cervical dislocation and the peritoneum 
was flushed with 4°C incubation buffer containing 
5 U/ml heparin. 3-5 x lo7 cells were obtained per 
rat and at least 87% were esterase positive [17], i.e. 
macrophages. Separate experiments showed that 
binding was trivial or absent in cells not adhering 
to plastic at 37”C, i.e. non-macrophages. 
Cells (1.6 x 106/ml) were incubated at 4°C with 
shaking in buffer containing 25 mM Hepes, 1% 
(w/v) bovine serum albumin and Krebs’ salts, pH 
7.6 [ 141. The incubations were terminated by the 
addition of 200 ~1 cell suspension to microfuge 
tubes containing 100 ~1 dibutylphthalate/dinonyl- 
phthalate (3 : 1) followed by centrifugation for 40 s 
in a Beckman microfuge and the cell pellets were 
recovered by cutting through the oil layer. About 
0.35% of the incubation buffer was trapped in the 
cell pellet when using this procedure [14]. The 
same percent of radioactivity was present in the 
cell pellet when a very large concentration of un- 
labelled arI3-chymotrypsin was present together 
with the labelled ligand (cf. fig.2). Thus, all bind- 
ing was displaceable or ‘specific’. 
3. RESULTS 
While it has been indicated earlier that com- 
plexes between rurI3 and proteinases are eliminated 
from the circulation in rats with a half-time of 
about 15 min [4], no attempt was made to identify 
the cells responsible for this. The recent realization 
that ~~113 is structurally related to the cu-macro- 
globulins suggested that arI3-proteinase complexes 
would bind to rat hepatocytes and macrophages. 
These cells are known from previous studies to 
contain receptors which recognize and internalize 
not only rat cuz-macroglobulin and cyr-macroglobu- 
lin but also human auz-macroglobulin and pregnan- 
cy zone protein [13-16,18,19]. curI3-chymotrypsin 
was used as a standard preparation for the fol- 
lowing studies in the rat. 
In vivo experiments showed that intravenously 
injected ‘251-labelled curI3-chymotrypsin disap- 
peared from the blood with a half-time of 
2.5 + 0.6 min (n = 6) whereas the half-time of un- 
complexed &,I3 was more than 60 min. By 6 min, 
lo-15% of the labelled curI3-chymotrypsin re- 
mained in the blood and 83 f 3% (n = 3) of the 
radioactivity taken up by the tissue was in the liver, 
whereas 2.5 f 0.3% was in the spleen. These 
numbers are indistinguishable from those obtained 
when ‘2SI-labelled human cuz-macroglobulin- 
trypsin [ 151 or the homologous pregnancy zone 
protein-chymotrypsin [ 181 are injected intra- 
venously into rats. This suggested that the cell 
types responsible for removal of these complexes 
from the circulation might also remove 
curI3-chymotrypsin. 
Table 1 shows the binding of curI3-proteinase 
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complexes to hepatocytes and macrophages as 
compared with the binding of cuz-macroglobulin- 
trypsin. c~iI3 complexed with chymotrypsin or 
trypsin showed the same specific binding to 
hepatocytes, and it was similar to that of human 
az-macroglobulin-trypsin. Uncomplexed alI 
showed much lower binding. Surprisingly, treat- 
ment with methylamine did not increase this bind- 
ing in spite of the complete cleavage of the thiol 
esters. However, incubation of methylamine- 
treated ai13 for 5 min with a 1.5-times molecular 
excess of chymotrypsin caused an increase in bind- 
ing to the same level as that of cuiI3-chymotrypsin. 
SDS-PAGE in the presence of mercaptoethanol 
demonstrated that this chymotrypsin treatment 
caused a fragmentation of cuilj-methylamine 
similar to that obtained after treatment of native 
ai13 [6], i.e. into a 96 kDa fragment and several 
fragments of low molecular mass (not shown). 
This indicates that ailj-methylamine, like native 
c~il3, is cleaved in the bait region and subsequently 
at several other sites [6]. 
Binding of LYI 13-chymotrypsin to hepatocytes 
was analyzed further at 4°C. Fig.1 shows a slow 
time course of binding at this temperature as 
previously observed for a2-macroglobulin and 
pregnancy zone protein complexes [ 14,181. The 
binding was almost identical for al13-chymotryp- 
sin and human cYl-macroglobulin-trypsin at tracer 
concentrations. Specific binding of labelled 
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Fig. 1. Time course of curI3-chymotrypsin binding to rat 
hepatocytes. The cells were incubated at 4°C for the 
times indicated. 40 pM ‘251-labelled curI3-chymotrypsin 
alone (M ), labelled cur13-chymotrypsin plus 200 nM 
unlabelled cyr I3-chymotrypsin (X-X), labelled ~13 plus 
100 nM cuz-macroglobulin-trypsin (M), 40 pM lz51- 
labelled uncomplexed (~113 (ti), 10 pM ‘251-labelled 
human cYz-macroglobulin-trypsin (M). 
200 nM unlabelled homologous ligand and 
markedly inhibited by 100 nM cuz-macroglobulin- 
trypsin. Similar data were obtained with macro- 
phages (not shown). This suggested that ai13 com- 
Table 1 
Binding of alI3 complexes to rat hepatocytes and peritoneal macrophages 
Labelled complex Percent specifically bound 
Hepatocytes Macrophages 
curI~chymotrypsin” 17.0 +- 1.6 7.1 + 0.7 
curlj-trypsinb 15.7 f 1.1 6.5 -t 0.4 
arl3 (uncomplexed) 2.1 t 0.6 0.5 f 0. I 
crrl~-methylamine 2.8 -t 0.3 1.4 + 0.3 
~u113-methylamine-chymotrypsin’ 20.7 f 1.9 8.0 k 0.6 
cu2-Macroglobulin-trypsin 18.2 -t 2.1 11.3 t 0.9 
a I .5-times molecular excess of chymotrypsin for 3 min 
b 50-times molecular excess of trypsin for 5 min; 3-times excess for 5 min gave 
only partial effect 
’ 1.5-times molecular excess for 5 min 
All complexes were prepared at 20°C as explained in the footnotes. Cells were 
incubated for 20 h at 4°C with approx. 20 pM of the indicated labelled ligands. 
The results are the mean values of 4 experiments + 1 SD 
Volume 221, number 1 FEBS LETTERS August 1987 
Fig.2. Concentration dependence of Lu,I3-chymotrypsin 
binding. Hepatocytes were incubated for 22 h at 4°C. 
Panel A shows the binding of 80 pM ‘251-labelled 
alIs-chymotrypsin plus unlabelled allx-chymotrypsin to 
give total concentrations as indicated on the abscissa 
(M). This curve represents the best least-square fit 
using a one-receptor model for reversible binding. The 
apparent & was 480 pM and R, was 96 pM. Competi- 
tion with human cuz-macroglobulin-trypsin (C--O) and 
with uncomplexed CY,I~ (M) are also shown. Panel B 
shows the binding of 20 pM ‘251-labelled uz-macro- 
globulin-trypsin plus unlabelled homologous ligand 
(M). This curve is computed using the best least- 
square fit for a two-receptor model. The inhibition by 
unlabelled cuI13-chymotrypsin is also shown (M). 
plexes, at least in part, were bound to the receptors 
for a*-macroglobulin-proteinase complexes. 
Fig. 2 shows the concentration dependence of 
a,l3-chymotrypsin binding, and the apparent 
dissociation constant was about 500 pM. Similar 
results were obtained when alI3 was complexd with 
58 
trypsin, elastase or S. aureus protease (not shown). 
The inhibition constant of uncomplexed ~11~ was 
approximately 4 nM. The mean apparent & value 
for olllJ-chymotrypsin binding in this and 3 similar 
experiments was 492 f 36 pM. Human 
cYz-macroglobulin-trypsin was less efficient and the 
inhibition curve was not parallel with that obtained 
when using unlabelled cull3-chymotrypsin, a 
phenomenon which was reproduced in several ex- 
periments. On the other hand, the 18 kDa receptor 
binding fragment obtained by digestion of 
az-macroglobulin-methylamine with papain [20] 
inhibited ‘251-labelled ~~113 or cuz-macroblobulin 
equally well (not shown). 
Fig. 2B shows, in agreement with previous 
results (141, that binding of human olz-macro- 
globulin-trypsin kinetically behaves according to a 
two-receptor model. This binding was completely 
abolished with high concentrations of of 
ollls-chymotrypsin confirming that this ligand is 
bound to the entire population of ol2-macroglobu- 
lin complex receptors. This result was also ob- 
tained in several experiments with macrophages 
(not shown). Other results may be summarized as 
follows (not shown). The dissociation of labelled 
oll13-chymotrypsin was very slow and similar to 
that obtained with human pregnancy zone protein 
complex [ 181. all3-chymotrypsin was taken up and 
degraded by hepatocytes at 37°C in a way similar 
to that observed for human [l4] and rat [13] 
ol2-macroglobulin-trypsin. This process was poorly 
competed for by human az-macroglobulin- 
proteinase complex and complete inhibition was 
not achieved even with 1 PM complex. On the 
other hand, olll3-chymotrypsin readily inhibited 
uptake of labelled az-macroglobulin complex and 
half-maximal inhibition was obtained with about 
10 nM ligand, a value similar to that obtained with 
unlabelled crz-macroglobulin-trypsin [ 151. 
4. DISCUSSION 
Previous results have shown that alI3 is a 
member of the macroglobulin family in the sense 
that proteinase, e.g. chymotrypsin, splits a peptide 
bond in the bait region, that an SH group is 
generated and that a stable al13-proteinase com- 
plex is formed [6-91. The present results 
demonstrate that the monomeric [8,9] cr113-chymo- 
trypsin binds to and is internalized via those recep- 
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tars in rat hepatocytes and macrophages which 
recognize both the tetrameric (e.g. human and rat 
olz-macroglobulin) and dimeric (pregnancy zone 
protein) cY-macroglobulins. 
The receptor binding domain of human 
ocz-macroglobulin is located in the C-terminal 
residues 1314-1451 [20,21]. The recently deter- 
mined partial sequence of the C-terminal 225 
residues of cur13 revealed several stretches with se- 
quences nearly identical to the equivalent stretches 
in ocz-macroglobulin 111. It therefore highly pro- 
bable that ~113 is a close homologue of 
az-macroglobulin with respect to sequence and 
location of the receptor binding determinants. 
The native a-macroglobulins all show very low 
receptor binding affinities in contrast to the high 
affinities exhibited by the cu-macroglobulin- 
proteinase complexes. It is well established that 
cleavage of the four thiol esters in the tetrameric 
human az-macroglobulin, for instance by incuba- 
tion with methylamine, is necessary and sufficient 
for obtaining optimal binding affinity [22,23]. It 
has therefore been proposed as a general mecha- 
nism for a-macroglobulins that thiol ester cleavage 
leads to the conformational change necessary for 
high receptor binding affinity [21-231. However, 
the cleavage of at least one peptide bond was 
necessary to bring about the high affinity confor- 
mation in alIs, in which the thiol esters were 
cleaved due to incubation with methylamine. This 
extends the previous observation that tetrameric 
rat cuz-macroglobulin was not converted to the high 
affinity form by incubation with methylamine 
[24]. In our hands, results were similar to the 
pregnancy zone protein: treatment with methyl- 
amine to cleave the two thiol esters failed to in- 
crease its affinity (Moestrup et al., unpublished). 
It has been proposed that the disulfide-bridged 
dimers might constitute the receptor binding unit 
of tetrameric or dimeric cu-macroglobulins [20,21]. 
The present finding that the monomeric alI3 binds 
with nearly the same affinity as the tetrameric 
human Luz-macroglobulin and dimeric pregnancy 
zone protein makes such a hypothesis unlikely. 
The following model may be proposed based on 
the present and previous data. The C-terminal ap- 
prox. 140 residue domain of an a-macroglobulin 
monomer contains the necessary information for 
receptor binding. However, the affinity of the en- 
tire monomer is, when complexed with a pro- 
teinase, about loo-times higher, probably because 
other parts of the monomer are necessary for 
maintaining the right conformation of the binding 
domain. Cleavage of the thiol esters is a necessary 
condition for obtaining the high affinity confor- 
mation. In some cases (e.g. human cy2-macro- 
globulin) it is also a sufficient condition whereas in 
other cases (e.g. rat ~~13 and rat a2-macroglobulin) 
cleavage of at least one bait region peptide bond is 
required. The presence of two or four domains in 
dimers and tetramers will cause quite subtle 
changes in the binding kinetics [18], as will the ex- 
tent of bait region cleavage in tetrameric human 
az-macroglobulin [25], but high affinity binding is 
not critically dependent on the quaternary struc- 
ture. 
In conclusion, the binding of the monomeric 
a~113 to the cuz-macroglobulin receptors indicates 
that dimeric or tetrameric structure is not 
necessary for high affinity receptor binding. This 
binding only occurs when at least one peptide bond 
in aiI3 is cleaved in the bait region and cleavage of 
the thiol ester is not sufficient to elicit the high af- 
finity conformation of the binding domain. 
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